Francisco Pasquel, MD
Enriched profileAssociate Professor of Medicine (Endocrinology, Metabolism and Lipids) and Global Health; Section Chief of Endocrinology, Emory University Hospital Midtown; Medical Director of Endocrinology, Grady Health System · Emory University School of Medicine
Francisco Pasquel is Associate Professor of Medicine (Endocrinology, Metabolism and Lipids) and Global Health; Section Chief of Endocrinology, Emory University Hospital Midtown; Medical Director of Endocrinology, Grady Health System at Emory University School of Medicine. OpenAlex indexes 256 publications with 6,537 citations (h-index 44); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Francisco Pasquel, MD, is Associate Professor of Medicine (Endocrinology, Metabolism and Lipids) and Global Health at Emory University School of Medicine, Division of Endocrinology, Metabolism and Lipids. The public record shows 256 publications with 6,537 citations (h-index 44), centered on Diabetes Management and Research, Hyperglycemia and glycemic control in critically ill and hospitalized patients, Diabetes Treatment and Management. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 5 companies, 3 NIH-funded awards (2018–2026).
- Most recent indexed publication: 2026 · Journal of diabetes science and technology
- Top research focus: Diabetes Management and Research
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 42 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 93.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
Sponsor: Indiana University
- Closed Loop Glucose Control in a Simulated ICU Setting
Sponsor: Ideal Medical Technologies
- GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Sponsor: Medtronic MiniMed, Inc.
Industry payments
Updated 27 Aug 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20254 payments
- Dexcom, Inc.Program year20232 payments
- SANOFI-AVENTIS U.S. LLCProgram year20221 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
75%GLP-1 receptor agonist34.7%Ozempic71%Trulicity18%Mounjaro12%Part D<11 patientsInsulin Analog29.8%Lantus Solostar34%Novolog Flexpen22%Tresiba Flextouch U-10019%Humalog Kwikpen U-10015%Levemir Flexpen11%Part D<11 patientsCardiovascular
19.9%Statin6.5%Atorvastatin Calcium100%Part D≥20 patientsCalcium channel blocker5.7%Amlodipine Besylate100%Part D≥15 patientsNervous system
5.1%Gabapentinoids5.1%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Automated Insulin Delivery for INpatients With DysGlycemia (AIDING)
Emory University
FY2026$696,267R01DK138366 - Automated Insulin Delivery for INpatients With DysGlycemia (AIDING)
Emory University
FY2025$719,735R01DK138366
Congress activity
Updated 27 Aug 2026
73 congress contributions (2013–2026) across AACE, ADA, ASCO, ENDO per OpenAlex. The most recent:
- 1063-OR: ADA Presidents' Select Abstract: Automated Insulin Delivery in Hospitalized Patients with Diabetes and Advanced Kidney Disease
ADA Scientific Sessions
ADA2026Co-authorOral - 1572-P: Clinical, Social, and Psychosocial Outcomes among Adults with Type 1 Diabetes in a Safety-Net Setting
ADA Scientific Sessions
ADA2026Co-authorPoster
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Continuous Glucose Monitoring in the Intensive Care Unit: A Multicenter, Retrospective Hospital-Based Analysis.
Journal of diabetes science and technology
Article2026 - Inpatient Use of Automated Insulin Delivery Systems.
Journal of diabetes science and technology
Review2026 - Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data.
Nature communications
Article2026 - Accuracy of Dexcom G6 Pro Continuous Glucose Monitor in the Intensive Care Setting: TIGHT ICU G6 Study.
Diabetes technology & therapeutics
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Management of diabetes and hyperglycaemia in the hospital309 citations2021
- 03
- 04
- 05Management of Hyperglycemic Crises270 citations2017
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/francisco-pasquel-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
medicine.emory.edu/endocrinology/faculty-directory/pasquel-francisco-javier.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.emory.edu ↗ - ResearchGate
researchgate.net/profile/Francisco-Pasquel-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
glytec.com/videos/enhancing-diabetes-care-with-technology-key-strategies-from-emory-university-and-grady-health-system
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →glytec.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →diabetes.emory.edu ↗
Editorial & leadership roles
journal and society appointments- Member
Southern Society for Clinical Investigation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ssciweb.org ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
Regional Technology Core, Georgia Center for Diabetes Translation Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →diabetes.emory.edu ↗ - Co-Director
Diabetes Translational Accelerator (DTA), Emory Global Diabetes Research Center (EGDRC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →diabetes.emory.edu ↗ - Medical Director of Endocrinology
Grady Health System
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →diabetes.emory.edu ↗
Media & interviews
press, podcasts and appearances- Featured speaker
"Enhancing Diabetes Care with Technology: Key Strategies from Emory University and Grady Health System", Becker's Healthcare/Glytec webinar on CGM adoption during COVID-19
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →glytec.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Arshed Quyyumi, MD
Emory University School of Medicine
Guillermo Umpierrez, MD
Emory University School of Medicine
Stewart Factor, DO
Emory University School of Medicine
Nadine Rouphael, MD
Emory University School of Medicine